PL2872646T3 - Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów - Google Patents
Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genówInfo
- Publication number
- PL2872646T3 PL2872646T3 PL13735334T PL13735334T PL2872646T3 PL 2872646 T3 PL2872646 T3 PL 2872646T3 PL 13735334 T PL13735334 T PL 13735334T PL 13735334 T PL13735334 T PL 13735334T PL 2872646 T3 PL2872646 T3 PL 2872646T3
- Authority
- PL
- Poland
- Prior art keywords
- predicting
- signature
- genes
- methods
- patient suffering
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000004043 responsiveness Effects 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 230000004083 survival effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305836 | 2012-07-12 | ||
| EP13735334.8A EP2872646B1 (en) | 2012-07-12 | 2013-07-12 | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| PCT/EP2013/064808 WO2014009535A2 (en) | 2012-07-12 | 2013-07-12 | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2872646T3 true PL2872646T3 (pl) | 2018-03-30 |
Family
ID=48782367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13735334T PL2872646T3 (pl) | 2012-07-12 | 2013-07-12 | Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11242564B2 (enExample) |
| EP (1) | EP2872646B1 (enExample) |
| JP (3) | JP6923291B2 (enExample) |
| DK (1) | DK2872646T3 (enExample) |
| ES (1) | ES2648176T3 (enExample) |
| NO (1) | NO2872646T3 (enExample) |
| PL (1) | PL2872646T3 (enExample) |
| WO (1) | WO2014009535A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11242564B2 (en) * | 2012-07-12 | 2022-02-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| WO2015094992A1 (en) | 2013-12-17 | 2015-06-25 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
| EP3084001A4 (en) * | 2013-12-17 | 2017-07-12 | Merck Sharp & Dohme Corp. | Gene signature biomarkers of tumor response to pd-1 antagonists |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| EP3232199B1 (en) * | 2014-08-19 | 2022-05-04 | National University Corporation Okayama University | Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer |
| US20170298443A1 (en) * | 2014-09-25 | 2017-10-19 | Moffitt Genetics Corporation | Prognostic tumor biomarkers |
| CA2966507A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment |
| MX2017005750A (es) | 2014-11-03 | 2017-12-15 | Genentech Inc | Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso. |
| EP3230498B1 (en) | 2014-12-09 | 2023-01-18 | Merck Sharp & Dohme LLC | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
| WO2016100975A1 (en) * | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
| WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| EP3073268A1 (en) * | 2015-03-27 | 2016-09-28 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Biomarker panel for diagnosing cancer |
| WO2016168133A1 (en) | 2015-04-17 | 2016-10-20 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
| CR20200476A (es) | 2015-05-20 | 2020-12-02 | Dana Farber Cancer Inst Inc | ANTÍGENOS COMPARTIDOS (Divisional 2017-0584) |
| WO2017065000A1 (ja) * | 2015-10-15 | 2017-04-20 | 国立大学法人京都大学 | Ｐｄ－１経路阻害薬の著効例を予測するためのバイオマーカー |
| US10968277B2 (en) | 2015-10-22 | 2021-04-06 | Jounce Therapeutics, Inc. | Gene signatures for determining ICOS expression |
| WO2017096458A1 (en) * | 2015-12-07 | 2017-06-15 | Ontario Institute For Cancer Research (Oicr) | Immune gene signature predictive of anthracycline benefit |
| AU2017250029C1 (en) * | 2016-04-15 | 2022-03-24 | Pfizer Inc. | Macrophage stimulation in CD47 blockade therapy |
| CN109690314B (zh) * | 2016-05-09 | 2022-08-02 | 法国国家卫生及研究医学协会 | 患有实体癌症的患者的分类方法 |
| EP3487522A4 (en) | 2016-07-19 | 2020-04-01 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
| WO2018045346A1 (en) * | 2016-09-01 | 2018-03-08 | Autotelic Llc | Methods for treating cancer and determining efficacy of treatment |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| CN110546277B (zh) | 2017-03-01 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| JP2020523022A (ja) * | 2017-06-14 | 2020-08-06 | アイカーン スクール オブ メディシン アット マウント サイナイ | 免疫療法に反応する肝細胞癌のクラスの検出および治療方法 |
| JP2020523991A (ja) * | 2017-06-16 | 2020-08-13 | ナントミクス，エルエルシー | Ｐｒａｅｇｎａｎｔ転移性乳癌コホートにおける不良アウトカムの予後指標因子 |
| WO2020245155A1 (en) | 2019-06-03 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for modulating a treatment regimen |
| IL291748A (en) | 2019-11-07 | 2022-06-01 | Oncxerna Therapeutics Inc | Classification of growth microenvironments |
| BR112022019112A2 (pt) | 2020-04-01 | 2022-11-08 | Avalo Therapeutics Inc | Métodos e tratamento envolvendo excesso de light livre |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| CN116209773A (zh) * | 2020-06-18 | 2023-06-02 | 宏观基因有限公司 | 双特异性CD123 x CD3双抗体用于治疗血液系统恶性肿瘤的用途 |
| WO2022002873A1 (en) | 2020-06-30 | 2022-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| EP4172628A1 (en) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
| CA3245129A1 (en) | 2022-03-17 | 2023-09-21 | Univ Paris Cite | METHODS FOR PREDICTING RESPONSE TO IMMUNOTHERAPEUTIC TREATMENT IN A CANCER PATIENT |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
| US6280929B1 (en) | 1986-01-16 | 2001-08-28 | The Regents Of The University Of California | Method of detecting genetic translocations identified with chromosomal abnormalities |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
| US5132432A (en) | 1989-09-22 | 1992-07-21 | Molecular Probes, Inc. | Chemically reactive pyrenyloxy sulfonic acid dyes |
| US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
| US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
| US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
| US5338854A (en) | 1991-02-13 | 1994-08-16 | Molecular Probes, Inc. | Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes |
| US5427932A (en) | 1991-04-09 | 1995-06-27 | Reagents Of The University Of California | Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using |
| US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
| US5262357A (en) | 1991-11-22 | 1993-11-16 | The Regents Of The University Of California | Low temperature thin films formed from nanocrystal precursors |
| US5505928A (en) | 1991-11-22 | 1996-04-09 | The Regents Of University Of California | Preparation of III-V semiconductor nanocrystals |
| US6048616A (en) | 1993-04-21 | 2000-04-11 | Philips Electronics N.A. Corp. | Encapsulated quantum sized doped semiconductor particles and method of manufacturing same |
| US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5571018A (en) | 1994-11-23 | 1996-11-05 | Motorola, Inc. | Arrangement for simulating indirect fire in combat training |
| US5690807A (en) | 1995-08-03 | 1997-11-25 | Massachusetts Institute Of Technology | Method for producing semiconductor particles |
| US5800996A (en) | 1996-05-03 | 1998-09-01 | The Perkin Elmer Corporation | Energy transfer dyes with enchanced fluorescence |
| US5830912A (en) | 1996-11-15 | 1998-11-03 | Molecular Probes, Inc. | Derivatives of 6,8-difluoro-7-hydroxycoumarin |
| US5696157A (en) | 1996-11-15 | 1997-12-09 | Molecular Probes, Inc. | Sulfonated derivatives of 7-aminocoumarin |
| US5866366A (en) | 1997-07-01 | 1999-02-02 | Smithkline Beecham Corporation | gidB |
| US6130101A (en) | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
| US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US6617583B1 (en) | 1998-09-18 | 2003-09-09 | Massachusetts Institute Of Technology | Inventory control |
| US6114038A (en) | 1998-11-10 | 2000-09-05 | Biocrystal Ltd. | Functionalized nanocrystals and their use in detection systems |
| US6855202B2 (en) | 2001-11-30 | 2005-02-15 | The Regents Of The University Of California | Shaped nanocrystal particles and methods for making the same |
| AU4701200A (en) | 1999-05-07 | 2000-11-21 | Quantum Dot Corporation | A method of detecting an analyte using semiconductor nanocrystals |
| US6225198B1 (en) | 2000-02-04 | 2001-05-01 | The Regents Of The University Of California | Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process |
| US6306736B1 (en) | 2000-02-04 | 2001-10-23 | The Regents Of The University Of California | Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process |
| US6500622B2 (en) | 2000-03-22 | 2002-12-31 | Quantum Dot Corporation | Methods of using semiconductor nanocrystals in bead-based nucleic acid assays |
| US6689338B2 (en) | 2000-06-01 | 2004-02-10 | The Board Of Regents For Oklahoma State University | Bioconjugates of nanoparticles as radiopharmaceuticals |
| DE60136719D1 (de) | 2000-08-04 | 2009-01-08 | Molecular Probes Inc | Kondensierte ringe enthaltende 1,2-dihydro-7-hydroxychinolinderivate |
| US6942970B2 (en) | 2000-09-14 | 2005-09-13 | Zymed Laboratories, Inc. | Identifying subjects suitable for topoisomerase II inhibitor treatment |
| US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
| US6670113B2 (en) | 2001-03-30 | 2003-12-30 | Nanoprobes | Enzymatic deposition and alteration of metals |
| US6709929B2 (en) | 2001-06-25 | 2004-03-23 | North Carolina State University | Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates |
| ATE556845T1 (de) | 2001-07-20 | 2012-05-15 | Life Technologies Corp | Lumineszierende nanopartikel und ihre herstellung |
| WO2004037996A2 (en) * | 2002-10-24 | 2004-05-06 | Duke University | Evaluation of breast cancer states and outcomes using gene expression profiles |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| US7642064B2 (en) | 2003-06-24 | 2010-01-05 | Ventana Medical Systems, Inc. | Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest |
| US7632652B2 (en) | 2003-06-24 | 2009-12-15 | Ventana Medical Systems, Inc. | Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences |
| AU2006239315B2 (en) | 2005-04-28 | 2012-03-01 | Ventana Medical Systems, Inc. | Enzymes conjugated to antiobodies via a PEG heterobifuctional linker |
| US20060246524A1 (en) | 2005-04-28 | 2006-11-02 | Christina Bauer | Nanoparticle conjugates |
| CN109485727A (zh) * | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| EP3095467B1 (en) | 2005-11-23 | 2020-05-06 | Ventana Medical Systems, Inc. | Antibody-enzyme conjugate |
| JP5984324B2 (ja) | 2005-12-01 | 2016-09-06 | メディカル プログノシス インスティテュート エー／エス | 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用 |
| US20100021424A1 (en) * | 2006-06-02 | 2010-01-28 | Vincent Brichard | Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy |
| CN101970664B (zh) * | 2008-01-16 | 2013-08-21 | 林希龙 | 使用可诱导的重组核糖核酸因子生成不含肿瘤的类胚胎干细胞的多能性细胞 |
| WO2010144192A1 (en) * | 2009-05-05 | 2010-12-16 | Children's Medical Center Corporation | Prognosis indicators for solid human tumors |
| AU2010276392A1 (en) * | 2009-07-20 | 2012-03-08 | Genentech, Inc. | Gene expression markers for Crohn's disease |
| CA2782620A1 (en) * | 2009-12-01 | 2011-06-09 | Compendia Bioscience, Inc. | Classification of cancers |
| US9404926B2 (en) * | 2010-01-29 | 2016-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
| US11242564B2 (en) * | 2012-07-12 | 2022-02-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
-
2013
- 2013-07-12 US US14/413,856 patent/US11242564B2/en active Active
- 2013-07-12 PL PL13735334T patent/PL2872646T3/pl unknown
- 2013-07-12 NO NO13735334A patent/NO2872646T3/no unknown
- 2013-07-12 WO PCT/EP2013/064808 patent/WO2014009535A2/en not_active Ceased
- 2013-07-12 ES ES13735334.8T patent/ES2648176T3/es active Active
- 2013-07-12 EP EP13735334.8A patent/EP2872646B1/en active Active
- 2013-07-12 DK DK13735334.8T patent/DK2872646T3/en active
- 2013-07-12 JP JP2015521016A patent/JP6923291B2/ja active Active
-
2019
- 2019-05-28 JP JP2019099354A patent/JP6936277B2/ja active Active
-
2021
- 2021-07-07 JP JP2021112781A patent/JP7378443B2/ja active Active
- 2021-12-27 US US17/562,111 patent/US12291752B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7378443B2 (ja) | 2023-11-13 |
| US11242564B2 (en) | 2022-02-08 |
| US20220259665A1 (en) | 2022-08-18 |
| US12291752B2 (en) | 2025-05-06 |
| ES2648176T3 (es) | 2017-12-28 |
| NO2872646T3 (enExample) | 2018-01-27 |
| EP2872646B1 (en) | 2017-08-30 |
| EP2872646A2 (en) | 2015-05-20 |
| JP6923291B2 (ja) | 2021-08-18 |
| DK2872646T3 (en) | 2017-12-04 |
| JP2021166539A (ja) | 2021-10-21 |
| JP6936277B2 (ja) | 2021-09-15 |
| JP2019162138A (ja) | 2019-09-26 |
| WO2014009535A3 (en) | 2014-04-17 |
| WO2014009535A2 (en) | 2014-01-16 |
| US20150203919A1 (en) | 2015-07-23 |
| JP2015528698A (ja) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2872646T3 (pl) | Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów | |
| HUE051674T2 (hu) | Eszközök és eljárások rákos beteg kezelésére adott válaszának elõrejelzésére | |
| IL263661A (en) | Combination therapy for the treatment of glioblastoma | |
| EP2652506A4 (en) | USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER | |
| LT2819663T (lt) | Nauji terapiniai parkinsono ligos gydymo būdai | |
| SMT201900024T1 (it) | Terapia combinata per il trattamento di cancro | |
| EP2651443A4 (en) | ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND THE MIGRATION OF CANCER CELLS | |
| IL237125A0 (en) | Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| IL228579A0 (en) | Methods for predicting and improving the survival of gastric cancer patients | |
| EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
| SMT201800604T1 (it) | Composti per il trattamento di obesita' e metodi di uso degli stessi | |
| GB201001412D0 (en) | Propolis and process for the treatment thereof | |
| EP2756302A4 (en) | METHODS OF PREDICTING AND REDUCING THE RISK OF PREMATURE BIRTH | |
| IL275636A (en) | Medical combination for cancer treatment | |
| EP2934501A4 (en) | USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES | |
| PL3351104T3 (pl) | Związki do stosowania w leczeniu okresowych zaburzeń wybuchowych | |
| IL229374A0 (en) | A signature for diagnosing cancer aggressiveness and genetic instability | |
| ZA201400488B (en) | Compounds for the treatment of cancers associated with human papillomavirus | |
| IL230880A0 (en) | A device for the stimulation of the heart and a control system for it | |
| HK1192775A (en) | Methods for predicting and improving the survival of gastric cancer patients | |
| IL233495A0 (en) | Combination for cancer treatment | |
| GB201112576D0 (en) | Therapeutic and diagnostic target | |
| GB201112567D0 (en) | Therapeutic and diagnostic target | |
| GB201112595D0 (en) | Therapeutic and diagnostic target |